Diagnostic and Management Approach to Abnormal Complete Blood Count (CBC)

Initial Evaluation and Diagnostic Workup

The American Society of Clinical Oncology recommends a detailed history and physical examination with special attention to previous lymphocyte-depleting therapies, personal or family history of autoimmune disease, nutritional status assessment, spleen size evaluation, and recent viral illnesses in patients with abnormal CBC results 1
The American Society of Clinical Oncology suggests careful review of specific abnormalities in the CBC, including examination for leukemic blasts or dysplastic changes, platelet count for thrombocytopenia risk, and mean corpuscular volume (MCV) which may indicate macrocytosis as a manifestation of myelodysplastic syndrome (MDS) 2

For patients with severe neutropenia (absolute neutrophil count <200/mm³), the American Society of Clinical Oncology recommends urgent hematology consultation and consideration of growth factor support 3
For patients with immune thrombocytopenia, the American Society of Clinical Oncology suggests consideration of prednisone 1 mg/kg/day (0.5-2 mg/kg/day) orally for 2-4 weeks with 4-6 week taper for Grade 2-3 cases, and hematology consultation and consideration of prednisone 1-2 mg/kg/day (oral or IV depending on symptoms) for Grade 4 cases 1

The American Society of Clinical Oncology recommends referral to hematology for severe cytopenias (Grade 3-4) affecting any cell line, multiple cell line abnormalities suggesting bone marrow failure, presence of blasts or significant dysplastic changes on peripheral smear, persistent unexplained cytopenias despite initial evaluation, and suspected hematologic malignancy based on clinical or laboratory findings 2, 1, 3
For patients at high risk for myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), the American Society of Clinical Oncology suggests performing CBC every 3-4 months for highest risk conditions, and every 6-12 months for moderate risk conditions if counts remain stable 2

Schedule a repeat CBC in 3 months to establish stability or identify any trend, as recommended by clinical guidelines, for a patient with a slightly decreased MCHC and otherwise normal CBC results 4

When confronted with an abnormal CBC, immediately obtain a detailed history and examine the peripheral blood smear to confirm true abnormalities and identify critical findings like blasts, dysplasia, or schistocytes, as recommended by the American Society of Clinical Oncology 5, 6

For Grade 1 thrombocytopenia, continue routine care with close clinical follow-up and laboratory monitoring, according to the American Society of Clinical Oncology 6
For Grade 2 thrombocytopenia, hold immunotherapy if applicable and consider prednisone 1 mg/kg/day orally for 2-4 weeks, then taper over 4-6 weeks if bleeding present, as recommended by the American Society of Clinical Oncology 6
For Grade 3-4 thrombocytopenia, immediate hematology consultation is required, and prednisone 1-2 mg/kg/day and IVIG 1 g/kg may be considered, according to the American Society of Clinical Oncology 6

For Grade 1-2 lymphopenia, continue routine care, as recommended by the American Society of Clinical Oncology 5, 6
For Grade 3 lymphopenia, continue care but check CBC weekly and initiate CMV screening, according to the American Society of Clinical Oncology 5, 6
For Grade 4 lymphopenia, consider holding immunotherapy and initiate Mycobacterium avium complex prophylaxis and Pneumocystis jirovecii prophylaxis, as recommended by the American Society of Clinical Oncology 5, 6

For patients with leukemia-predisposing conditions, annual bone marrow evaluation is recommended for those at higher risk of MDS/AML even with stable counts, according to the National Comprehensive Cancer Network 7

Overlooking medication history that may cause cytopenias is a common pitfall, as highlighted by the American Society of Clinical Oncology 5, 6